Differences in the availability of new anti-cancer drugs for Italian patients treated in different regions. Results of analysis conducted by the Italian Society of Medical Oncology (AIOM)

Stefania Gori, Massimo Di Maio, Carmine Pinto, Oscar Alabiso, Editta Baldini, Giordano Domenico Beretta, Orazio Caffo, Cinzia Caroti, Lucio Crinò, Michelino De Laurentiis, Angelo Dinota, Francesco Di Vito, Vittorio Gebbia, Lucio Giustini, Claudio Graiff, Michele Guida, Giorgio Lelli, Marco Lombardo, Antonio Muggiano, Fabio PuglisiSante Romito, Luigi Salvagno, Pierosandro Tagliaferri, Edmondo Terzoli, Marco Venturini

Research output: Contribution to journalArticle

Abstract

Aims and background. Italy is divided into 20 regions. As a consequence of local autonomy, following marketing authorization by the Italian Medicines Agency, each drug for hospital use is not immediately available, because its approval needs to undergo further steps that can be different among regions. The Italian Society of Medical Oncology conducted the present study to describe the impact of the existence of sub-national pharmaceutical formularies on the disparity of access to new anti-cancer drugs among patients treated in different Italian regions. Methods. The availability of 8 new anti-cancer drugs at a regional level and the coherence of regional authorizations compared with national authorizations approved by the Italian Medicines Agency were analyzed as of April 2009. Results. Fifteen regions and autonomous province of Trento have a regional pharmaceutical formulary. In most cases, the regional pharmaceutical formularies include the eight analyzed drugs, with therapeutic indications coherent with national marketing authorization indications. Five drugs (bevacizumab, trastuzumab, rituximab, erlotinib, sunitinib) were included in all the existing regional pharmaceutical formularies, without restrictions, whereas three drugs (cetuximab, sorafenib, pemetrexed) were found to have restrictions in some regions. Conclusions. The presence of multiple hierarchical levels of drug evaluation creates a potential element of disparity in the access to pharmacological therapies for Italian citizens. Free full text available at www.tumorionline.it.

Original languageEnglish
Pages (from-to)1010-1015
Number of pages6
JournalTumori
Volume96
Issue number6
Publication statusPublished - Nov 2010

Keywords

  • Anticancer drugs
  • Disparity
  • Reimbursement

ASJC Scopus subject areas

  • Cancer Research
  • Oncology

Fingerprint Dive into the research topics of 'Differences in the availability of new anti-cancer drugs for Italian patients treated in different regions. Results of analysis conducted by the Italian Society of Medical Oncology (AIOM)'. Together they form a unique fingerprint.

  • Cite this

    Gori, S., Di Maio, M., Pinto, C., Alabiso, O., Baldini, E., Beretta, G. D., Caffo, O., Caroti, C., Crinò, L., De Laurentiis, M., Dinota, A., Di Vito, F., Gebbia, V., Giustini, L., Graiff, C., Guida, M., Lelli, G., Lombardo, M., Muggiano, A., ... Venturini, M. (2010). Differences in the availability of new anti-cancer drugs for Italian patients treated in different regions. Results of analysis conducted by the Italian Society of Medical Oncology (AIOM). Tumori, 96(6), 1010-1015.